Table 2.

Body Composition in Men With Abdominal Obesity Treated With GH vs Placebo for 6 Months^a

Variable	Treatment	Baseline (n = 62)	6 wk (n = 58)	6 mo (n = 43)	Effect Size ± SE	Pb
n	GH	32	31	22
	Placebo	30	27	21
Weight, kg	GH	115 ± 3	116 ± 3	116 ± 4	1.2 ± 1.1	.3
	Placebo	122 ± 4	123 ± 5	128 ± 6
BMI, kg/m2	GH	36.4 ± 0.9	36.6 ± 1.0	36.8 ± 1.3	0.4 ± 0.3	.2
	Placebo	37.7 ± 1.2	38.0 ± 1.3	40.0 ± 1.8
VAT/SAT	GH	0.38 ± 0.04	0.34 ± 0.03	0.31 ± 0.05	−0.06 ± 0.02	.01c
	Placebo	0.35 ± 0.03	0.36 ± 0.03	0.36 ± 0.04
Abdomen VAT, cm2	GH	157.5 ± 12.2	149.2 ± 11.1	134.6 ± 13.9	−12.4 ± 9.4	.2c
	Placebo	158.3 ± 10.5	158.2 ± 12.7	161.4 ± 15.8
Abdomen SAT, cm2	GH	450.1 ± 23.8	453.6 ± 22.0	443.8 ± 30.5	12.2 ± 13.2	.4
	Placebo	464.9 ± 28.4	454.3 ± 29.8	467.6 ± 36.2
Thigh SAT, cm2	GH	143.7 ± 9.2	141.8 ± 9.2	142.1 ± 12.5	2.3 ± 5.0	.6
	Placebo	146.1 ± 11.6	153.8 ± 14.6	165.0 ± 19.6
Thigh muscle, cm2	GH	207.0 ± 5.1	209.8 ± 5.7	212.6 ± 6.5	1.0 ± 2.6	.7
	Placebo	219.7 ± 6.2	218.7 ± 5.6	220.0 ± 7.1
Total body fat, kge	GH	40.1 ± 2.0	40.3 ± 2.6	40.4 ± 2.7	−2.4 ± 3.0	.9
	Placebo	42.2 ± 2.9	44.2 ± 3.5	46.7 ± 4.6
Trunk/extremity fate	GH	1.24 ± 0.04	1.21 ± 0.04	1.19 ± 0.04	−0.07 ± 0.02	.005c
	Placebo	1.17 ± 0.04	1.18 ± 0.04	1.24 ± 0.04
Total lean mass, kge	GH	73.7 ± 1.6	74.7 ± 1.8	74.4 ± 2.0	0.3 ± 1.2	.8
	Placebo	78.6 ± 1.9	78.3 ± 1.8	78.6 ± 2.0
Total body water/lean	GH	59.8 ± 1.4	61.0 ± 1.5	61.3 ± 1.9	0.3 ± 1.2	.8
body mass	Placebo	63.7 ± 1.9	64.4 ± 1.9	65.8 ± 2.3
IMCL-SOL (lipid/water)	GH	0.05 ± 0.007	0.04 ± 0.008	0.04 ± 0.01	0.005 ± 0.008	.5
	Placebo	0.04 ± 0.005	0.04 ± 0.006	0.03 ± 0.005
IHL (lipid/water)	GH	0.19 ± 0.05	0.25 ± 0.06	0.11 ± 0.03	−0.04 ± 0.03	.1c
	Placebo	0.23 ± 0.1	0.19 ± 3.0	0.26 ± 0.08
PCr recovery constant τ (sec) (mitochondrial function)	GH	35.1 ± 2.2	30.9 ± 2.4	33.2 ± 2.3	−6.1 ± 4.4	.2d
	Placebo	29.5 ± 2.5	31.5 ± 2.5	36.8 ± 3.9

Abbreviation: IMCL-SOL, IMCL concentration of soleus.

^aData are presented as mean ± SEM.

^bP between groups (0–6 months) determined by repeated-measures ANOVA without controlling for change in weight.

^csignificant (P ≤ .05) after controlling for 6-month change in weight

^dsignificant (P ≤ .05) after controlling for 6-month change in glucose area under the curve

^eDXA was performed at baseline and 3 and 6 months.